Real-world studies also confirmed that injectable GLP1-RAs are underused, and prescribed predominantly in patients with a long history of cardiovascular disease and with high mean HbA1c values (>8.2%) [13]. The gene discussed is GLP1R; the disease is cardiovascular disorder.